Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?
Rebecca L
RL
Roberts
Richard B
RB
Gearry
Murray L
ML
Barclay
D000493:Allopurinol / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001379:Azathioprine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D001711:Biotransformation / Q000235:genetics; D056486:Chemical and Drug Induced Liver Injury / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control; D004359:Drug Therapy, Combination; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics*; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
D000493:Allopurinol; D015122:Mercaptopurine; D014969:Xanthine Oxidase; D001379:Azathioprine